Menu
Search
|

Menu

Close
X

Idera Pharmaceuticals Inc IDRA.OQ (NASDAQ Stock Exchange Capital Market)

7.04 USD
-1.46 (-17.18%)
As of Oct 19
chart
Previous Close 8.50
Open 8.50
Volume 115,604
3m Avg Volume 111,444
Today’s High 8.56
Today’s Low 6.91
52 Week High 20.40
52 Week Low 5.22
Shares Outstanding (mil) 27.17
Market Capitalization (mil) 236.68
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.71 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
1
FY16
16
FY15
0
EPS (USD)
FY18
-1.399
FY17
-3.392
FY16
-2.540
FY15
-3.388
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.14
Price to Sales (TTM)
vs sector
313.49
6.55
Price to Book (MRQ)
vs sector
2.78
4.00
Price to Cash Flow (TTM)
vs sector
--
21.51
Total Debt to Equity (MRQ)
vs sector
0.00
14.15
LT Debt to Equity (MRQ)
vs sector
0.00
11.31
Return on Investment (TTM)
vs sector
-81.24
12.83
Return on Equity (TTM)
vs sector
-82.01
14.95

EXECUTIVE LEADERSHIP

James Geraghty
Independent Chairman of the Board, Since 2013
Salary: --
Bonus: --
Vincent Milano
President, Chief Executive Officer, Director, Since 2014
Salary: $50,000.00
Bonus: --
Louis Arcudi
Chief Financial Officer, Since 2018
Salary: $327,600.00
Bonus: $98,300.00
Bryant Lim
Senior Vice President, General Counsel, Secretary, Since 2018
Salary: --
Bonus: --
Robert Fletcher
Senior Vice President - Business Development and Strategic Planning, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

505 Eagleview Blvd Ste 212
EXTON   PA   19341-1199

Phone: +1484.3481600

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.

SPONSORED STORIES